These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1954 related articles for article (PubMed ID: 23352604)
1. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study). Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604 [TBL] [Abstract][Full Text] [Related]
2. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258 [TBL] [Abstract][Full Text] [Related]
3. Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial. Skof E; Rebersek M; Hlebanja Z; Ocvirk J BMC Cancer; 2009 Apr; 9():120. PubMed ID: 19386096 [TBL] [Abstract][Full Text] [Related]
4. XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions. Uygun K; Bilici A; Kaya S; Oven Ustaalioglu BB; Yildiz R; Temiz S; Seker M; Aksu G; Cabuk D; Gumus M Asian Pac J Cancer Prev; 2013; 14(4):2283-8. PubMed ID: 23725128 [TBL] [Abstract][Full Text] [Related]
5. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study. Bennouna J; Borg C; Delord JP; Husseini F; Trillet-Lenoir V; Faroux R; François E; Ychou M; Goldwasser F; Bouché O; Senellart H; Kraemer S; Douillard JY Clin Colorectal Cancer; 2012 Mar; 11(1):38-44. PubMed ID: 21803002 [TBL] [Abstract][Full Text] [Related]
6. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer. Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Chin K; Yamaguchi T Drug Des Devel Ther; 2015; 9():1653-62. PubMed ID: 25834402 [TBL] [Abstract][Full Text] [Related]
7. Capecitabine plus irinotecan versus 5-FU/leucovorin plus irinotecan in the treatment of colorectal cancer: a meta-analysis. Guo Y; Shi M; Shen X; Yang C; Yang L; Zhang J Clin Colorectal Cancer; 2014 Jun; 13(2):110-8. PubMed ID: 24461997 [TBL] [Abstract][Full Text] [Related]
8. A phase I/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX study). Hamamoto Y; Yamaguchi T; Nishina T; Yamazaki K; Ura T; Nakajima T; Goto A; Shimada K; Nakayama N; Sakamoto J; Morita S; Yamada Y Oncologist; 2014 Nov; 19(11):1131-2. PubMed ID: 25280489 [TBL] [Abstract][Full Text] [Related]
9. A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer. Lim SH; Kim TW; Hong YS; Han SW; Lee KH; Kang HJ; Hwang IG; Lee JY; Kim HS; Kim ST; Lee J; Park JO; Park SH; Park YS; Lim HY; Jung SH; Kang WK Br J Cancer; 2015 Nov; 113(10):1421-6. PubMed ID: 26505681 [TBL] [Abstract][Full Text] [Related]
10. Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study. Jackson NA; Barrueco J; Soufi-Mahjoubi R; Marshall J; Mitchell E; Zhang X; Meyerhardt J Cancer; 2009 Jun; 115(12):2617-29. PubMed ID: 19382200 [TBL] [Abstract][Full Text] [Related]
11. Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer. Montagnani F; Chiriatti A; Licitra S; Aliberti C; Fiorentini G Clin Colorectal Cancer; 2010 Oct; 9(4):243-7. PubMed ID: 20920997 [TBL] [Abstract][Full Text] [Related]
12. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966 [TBL] [Abstract][Full Text] [Related]
13. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Tabernero J; Van Cutsem E; Lakomý R; Prausová J; Ruff P; van Hazel GA; Moiseyenko VM; Ferry DR; McKendrick JJ; Soussan-Lazard K; Chevalier S; Allegra CJ Eur J Cancer; 2014 Jan; 50(2):320-31. PubMed ID: 24140268 [TBL] [Abstract][Full Text] [Related]
14. Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC). Souglakos J; Ziras N; Kakolyris S; Boukovinas I; Kentepozidis N; Makrantonakis P; Xynogalos S; Christophyllakis Ch; Kouroussis Ch; Vamvakas L; Georgoulias V; Polyzos A Br J Cancer; 2012 Jan; 106(3):453-9. PubMed ID: 22240792 [TBL] [Abstract][Full Text] [Related]
15. Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. Carrato A; Swieboda-Sadlej A; Staszewska-Skurczynska M; Lim R; Roman L; Shparyk Y; Bondarenko I; Jonker DJ; Sun Y; De la Cruz JA; Williams JA; Korytowsky B; Christensen JG; Lin X; Tursi JM; Lechuga MJ; Van Cutsem E J Clin Oncol; 2013 Apr; 31(10):1341-7. PubMed ID: 23358972 [TBL] [Abstract][Full Text] [Related]
16. Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials. García Alfonso P; Muñoz Martin A; Alvarez Suarez S; Blanco Codeidido M; Mondejar Solis R; Tapia Rico G; López Martín P; Martin M Onkologie; 2013; 36(6):363-7. PubMed ID: 23774151 [TBL] [Abstract][Full Text] [Related]
17. FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study. Kochi M; Akiyama Y; Aoki T; Hagiwara K; Takahashi T; Hironaka K; Teranishi F; Osuka F; Takeuchi M; Fujii M; Nakajima T Cancer Chemother Pharmacol; 2013 Nov; 72(5):1097-102. PubMed ID: 24057041 [TBL] [Abstract][Full Text] [Related]
18. Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab. Kotaka M; Xu R; Muro K; Park YS; Morita S; Iwasa S; Uetake H; Nishina T; Nozawa H; Matsumoto H; Yamazaki K; Han SW; Wang W; Ahn JB; Deng Y; Cho SH; Ba Y; Lee KW; Zhang T; Satoh T; Buyse ME; Ryoo BY; Shen L; Sakamoto J; Kim TW Chin J Cancer; 2016 Dec; 35(1):102. PubMed ID: 28007025 [TBL] [Abstract][Full Text] [Related]
19. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Masi G; Loupakis F; Salvatore L; Fornaro L; Cremolini C; Cupini S; Ciarlo A; Del Monte F; Cortesi E; Amoroso D; Granetto C; Fontanini G; Sensi E; Lupi C; Andreuccetti M; Falcone A Lancet Oncol; 2010 Sep; 11(9):845-52. PubMed ID: 20702138 [TBL] [Abstract][Full Text] [Related]
20. Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. Schmiegel W; Reinacher-Schick A; Arnold D; Kubicka S; Freier W; Dietrich G; Geißler M; Hegewisch-Becker S; Tannapfel A; Pohl M; Hinke A; Schmoll HJ; Graeven U Ann Oncol; 2013 Jun; 24(6):1580-7. PubMed ID: 23463625 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]